Camel-IDS (www.camel-ids.com), incorporated in 2014 as a spin-off company of Vrije Universiteit Brussel (VUB), develops novel radiopharmaceuticals, using camelid single domain antibody fragments (sdAbs) labeled with radioisotopes. The company’s lead product CAM-H2, a new treatment option in HER2-positive cancers, is in early clinical development. The pipeline further consists of two pre-clinical programs leveraging the technology strengths. In November 2018 Camel-IDS secured EUR 37m in a Series A investment round led by V-Bio Ventures (Belgium) and Gimv (Belgium), joined by HealthCap (Sweden), Novo Seeds (Denmark), Pontifax (Israel), BioMedPartners (Switzerland) as well as the seed investors. Since the start, Camel-IDS has received non-dilutive funding from Innoviris.